طب نساء وتوليد
Non-Clinical Interventions to reduce overall cesarean sections
“last update: 8 February 2024”
– Executive summary
➡️Introduction
The number of women who deliver by Cesarean section has increased steadily in Egypt over the last three decades, from 4.6% in 1992 (1) to 51.8% in 2014 (2).
Cesarean birth is associated with short- and long-term risks that can extend many years beyond the current delivery and affect the health of the woman, the child, and future pregnancies. High rates of cesarean section are associated with substantial health-care costs (3).
The factors contributing to the rise in cesarean section rates are complex, and identifying interventions to address them is challenging. Factors associated with cesarean births include changes in the characteristics of the population such as increase in the prevalence of multiple pregnancies, assisted reproduction, and increase in the proportion of nulliparous women with advanced age. Other non-clinical factors such as women increasingly wanting to determine how and when their child is born, generational shifts in work and family responsibilities, physician factors, increasing fear of medical litigation, as well as organizational, economic and social factors have all been implicated in this increase (4).
The sustained, unprecedented rise in cesarean section rates in Egypt is a major public health concern. There is an urgent need for evidence-based guidance to address the trend. This is the national guideline on non-clinical interventions (defined as interventions applied independently of a clinical encounter between a health-care provider and a patient in the context of patient care).
The objective of this guideline is to provide evidence-based recommendations on non-clinical interventions specifically designed to reduce cesarean sections. Clinical interventions that could help to reduce cesarean section rates are being prepared in a second guideline.
➡️Target audience
The primary audience for this guideline includes health-care professionals including obstetricians, midwives, nurses, and general medical practitioners, as well as managers of maternal and child health programs and public health policymakers in Egypt.
➡️Guideline development methods
We used the GRADE-Adolopment methodology for the guideline adaptation process (5). Briefly, this included, identifying and training guideline panelists, prioritizing questions and outcomes, identifying existing guideline (6), assessing quality and adaptability of the identified guideline, reviewing GRADE evidence tables and EtD frameworks, and formulating and grading strength of recommendations.
The identified existing guideline was developed by the WHO in accordance with standard procedures set out in the WHO handbook for guideline development (7). The evidence, in the identified guideline, on the effectiveness of interventions was derived from an updated Cochrane review of 29 studies (8).
Rationalizing the use of caesarean section in Egypt through implementing 10 group Classification system
“last update: 12 June 2025 Download Guideline
– Objectives
· Be aware of the cs rate and its burden on health system .
· Help you to recognize the absolute indications of cs .
· Help you in assessing and validating the relative indications of CS.
· Helps you to understand and implement the Robson Classification and build the Report Table using your own data
· Identify the complications of CS
· To help healthcare facilities and obstetricians in adopting and using the Robson Classification. It presents a standard approach to implement and interpret this classification
· Explains the variables and definitions used and how to produce and interpret the Report Table
· Highlights challenges that you may encounter and shares useful experiences and examples from users
The diagnosis and management of ectopic pregnancy & pregnancy of unknown location
“last update: 2 July 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on the management of ectopic pregnancy and pregnancy of unknown location. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of ectopic pregnancy resulting in improving health outcomes for people with this potentially fatal condition.
List of Recommendations:
|
Recommendation |
Strength |
|
Counselling and documentation |
|
|
Women should be given information at the time of diagnosis of an ectopic pregnancy regarding their diagnosis and management. They should be counselled regarding signs of clinical deterioration when they should present for review and given information about emergency contacts |
Strong |
|
Diagnosis of tubal ectopic pregnancy |
|
|
A urinary beta-human chorionic gonadotrophin (β-hCG) test should be performed in all women of reproductive age presenting to a maternity or adult general hospital/unit with abdominal pain, vaginal bleeding, gastrointestinal symptoms, dizziness, or collapse |
Strong |
|
A thorough gynaecological, obstetric, medical, and surgical history should be taken to assess for risk factors for ectopic pregnancy in women who present with the above symptoms; however, half of women with an ectopic pregnancy will have no known risk factors |
Strong |
|
A physical examination, including measurement of vital signs, should be performed to assess haemodynamic stability in women presenting with the above symptoms |
Strong |
|
There should be prompt escalation of care if there are any red flag symptoms on triage assessment or abnormal vital signs in the presence of a positive urinary HCG |
Strong |
|
All the above women are recommended to undergo ultrasound scanning |
GPS |
|
Consider a transabdominal ultrasound scan for women with an enlarged uterus or other pelvic pathology, such as fibroids or an ovarian cyst |
Conditional |
|
Offer women who attend an early pregnancy a transvaginal ultrasound scan to identify the location of the pregnancy and whether there is a fetal pole and heartbeat. If a transvaginal ultrasound scan is unavailable or unacceptable to the woman, offer a transabdominal ultrasound scan and explain the limitations of this method of scanning |
Strong |
|
When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating there is a tubal ectopic pregnancy: An adnexal mass, moving separate to the ovary, comprising a gestational sac containing a yolk sac and/or fetal pole (with or without fetal heartbeat) |
GPS |
|
When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating a high probability of a tubal ectopic pregnancy: An adnexal mass, moving separately to the ovary, with an empty gestational sac (“tubal ring” or “bagel sign”) or a complex, inhomogeneous adnexal mass, moving separate to the ovary. If these features are present, take into account other intrauterine and adnexal features on the scan, the woman’s clinical presentation, and serum HCG levels before making a diagnosis |
GPS |
|
When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating a possible ectopic pregnancy: An empty uterus or collection of fluid within the uterine cavity (pseudo-sac). If these features are present, take into account other intrauterine and adnexal features on the scan, the woman’s clinical presentation, and serum HCG levels before making a diagnosis |
GPS |
|
When carrying out a transabdominal or transvaginal ultrasound scan in early pregnancy, look for a moderate to large amount of free fluid in the peritoneal cavity or pouch of Douglas, which might represent hemoperitoneum. If this is present, take into account other intrauterine and adnexal features of the scan, the woman’s clinical presentation, and HCG levels before making a diagnosis |
GPS |
|
When carrying out a transabdominal or transvaginal ultrasound scan during early pregnancy, scan the uterus and adnexa to see if there is a heterotopic pregnancy |
GPS |
|
All ultrasound scans should be performed or directly supervised and reviewed by appropriately qualified healthcare professionals with training in, and experience of, diagnosing ectopic pregnancies |
GPS |
|
Be aware that women with a pregnancy of unknown location could have an ectopic pregnancy until the location is determined |
Conditional |
|
Do not use serum HCG measurements to determine the location of the pregnancy |
Strong |
|
In a woman with a pregnancy of unknown location, place more importance on clinical symptoms than on serum HCG results, and review the woman’s condition if any of her symptoms change, regardless of previous results and assessments |
Strong |
|
Use serum HCG measurements only for assessing trophoblastic proliferation to help to determine subsequent management |
Strong |
|
Take 2 serum HCG measurements as near as possible to 48 hours apart (but no earlier) to determine subsequent management of a pregnancy of unknown location. Take further measurements only after review by a senior healthcare professional |
Strong |
|
Regardless of serum HCG levels, women with a pregnancy of unknown location should be counseled about what to do if they experience any new or worsening symptoms, including details about how to access emergency care 24 hours a day. Advise women to return if there are new symptoms or if existing symptoms worsen |
Strong |
|
For a woman with an increase in serum HCG levels greater than 63% after 48 hours: – Inform her that she is likely to have a developing intrauterine pregnancy (although the possibility of an ectopic pregnancy cannot be excluded). – Offer her a transvaginal ultrasound scan to determine the location of the pregnancy between 7 and 14 days later. Consider an earlier scan for women with a serum HCG level greater than or equal to 1,500 IU/liter. – If a viable intrauterine pregnancy is confirmed, offer her routine antenatal care. – If a viable intrauterine pregnancy is not confirmed, refer her for immediate clinical review by a senior gynaecologist |
Strong |
|
For a woman with a decrease in serum HCG levels greater than 50% after 48 hours: inform her that the pregnancy is unlikely to continue but that this is not confirmed and provide her with information about where she can access support and counselling services. Ask her to take a urine pregnancy test 14 days after the second serum HCG test, and explain that: – if the test is negative, no further action is necessary. – if the test is positive, she should return to the early pregnancy assessment service for clinical review within 24 hours |
Strong |
|
For a woman with a decrease in serum HCG levels less than 50%, or an increase less than 63%, refer her for clinical review in the early pregnancy assessment service within 24 hours |
Strong |
|
For women with a pregnancy of unknown location, when using serial serum HCG measurements, do not use serum progesterone measurements as an adjunct to diagnose either viable intrauterine pregnancy or ectopic pregnancy. |
Strong |
|
Diagnosis of Pregnancy of unknown location |
|
|
Pregnancy of unknown location is a transient state in the diagnostic process, leading to a final diagnosis of viable or nonviable intrauterine pregnancy, ectopic pregnancy, or persistent pregnancy of unknown location |
Strong |
|
If pregnancy location cannot be determined on a TVUS, serial serum β-hCG measurements should be used in conjunction with a woman’s history and symptoms to guide management |
Strong |
|
Diagnosis of interstitial/cornual pregnancy |
|
|
Interstitial: Many are diagnosed at first trimester scanning by the presence of an eccentric gestational sac. A thin surrounding myometrial layer helps to distinguish this from an angular intrauterine pregnancy. A further sonographic sign is the presence of an echogenic line running from the endometrial cavity to the gestational sac |
GPS |
|
Cornual: Presentation may be delayed and is usually with abdominal pain. About 50% present after rupture and morbidity is high. The sensitivity of ultrasound diagnosis is low. The appearance is of a gestation sac separate from an empty unicornuate uterus which is identified by the single interstitial tube. The sac is mobile and surrounded by a thick myometrial layer. A vascular pedicle may be seen joining the gestational sac and the lateral aspect of the empty unicornuate uterus. |
GPS |
|
Diagnosis of Cervical pregnancy |
|
|
Implantation is within the cervical canal. Common predisposing factors are curettage, caesarean section or cervical surgical procedures. Usually, the first complaint is of painless vaginal bleeding and speculum examination may reveal an open external cervical os with a fleshy mass protruding |
Conditional |
|
Ultrasound shows a gestation sac distal to a closed internal cervical os. Doppler demonstration of surrounding vasculature helps distinguish a cervical pregnancy from a displaced intrauterine pregnancy. In addition, gentle pressure with the transvaginal probe may elicit the “sliding sign” whereby a miscarrying sac is seen to slide within the cervical canal unlike the cervical pregnancy which is fixed |
GPS |
|
Diagnosis of ovarian pregnancy |
|
|
Apart from the few cases with a clear-cut yolk sac or fetal pole visible in the ovary, ultrasound diagnosis is difficult. The ring surrounding an EP usually shows greater echogenicity than the surrounding ovarian tissue unlike the ring of a corpus luteum cyst which is less echogenic. If laparoscopy for suspected EP reveals that the tubes are normal a close inspection of the ovaries should be performed. Typically, an ovarian EP has the appearance of a cystic haemorrhagic mass |
GPS |
|
Diagnosis of abdominal pregnancy |
|
|
Diagnosis is difficult and is usually made intraoperatively |
GPS |
|
Diagnosis of CS scar pregnancy |
|
|
Ultrasound imaging is the primary imaging modality for CSEP diagnosis, although a correct and timely determination can be difficult. The initial finding of a low, anteriorly located gestational sac should raise concern for a possible CSEP and warrants further investigation |
Strong |
|
Transvaginal ultrasound imaging is the optimal modality for the evaluation of suspected CSEP because it provides the highest image resolution. Grayscale combined with color Doppler ultrasound imaging is recommended for CSEP diagnosis |
Strong |
|
US criteria to diagnose CSEP: (1) an empty uterine cavity and endocervix; (2) placenta, gestational sac, or both embedded in the hysterotomy scar; (3) a triangular (at 8 weeks of gestation) or rounded or oval (at >8 weeks of gestation) gestational sac that fills the scar “niche” (the shallow area representing a healed hysterotomy site); (4) a thin (< 3 mm) or absent myometrial layer between the gestational sac and bladder; (5) a prominent or rich vascular pattern at or in the area of a cesarean scar; and (6) an embryonic or fetal pole, yolk sac, or both, with or without fetal cardiac activity. All of these criteria may not be observed especially with very early diagnosis and before fetal cardiac activity, the patient should have confirmation of pregnancy (for example, a positive pregnancy test result). Bulging or ballooning of the lower uterine segment in the midline sagittal transabdominal view has also been considered to be supportive of CSEP diagnosis |
Strong |
|
In cases in which ultrasound imaging is inconclusive, MRI could be considered as an adjunct study. Given the risks associated with delayed diagnosis |
Conditional |
|
Hysteroscopy and laparoscopy can be used to confirm a diagnosis at the time of planned operative intervention. With laparoscopic examination, CSEP has been described as an ecchymotic bulge with a “salmon-red” appearance beneath the bladder at the level of the previous cesarean scar with an otherwise normal-appearing uterus |
Conditional |
|
Expectant management of tubal ectopic pregnancy |
|
|
Offer expectant management as an option to women who: – Are clinically stable and pain-free and – Have a tubal ectopic pregnancy measuring <35 mm with no visible heartbeat on transvaginal ultrasound scan and – Have serum hCG levels of ≤1000 IU/L and – Are able to return for follow-up |
Strong |
|
For women with a tubal ectopic pregnancy being managed expectantly, repeat hCG levels on days 2, 4, and 7 after the original test, and: – If hCG levels drop by ≥15% from the previous value on days 2, 4, and 7, then repeat weekly until a negative result (<20 IU/L) is obtained – If hCG levels do not fall by 15%, stay the same, or rise from the previous value, review the woman’s clinical condition and seek senior advice to help decide further management |
Strong |
|
Advise women that, based on limited evidence, there seems to be no difference following expectant or medical management in: – The rate of ectopic pregnancies ending naturally – The risk of tubal rupture – The need for additional treatment, but that they might need to be admitted urgently if their condition deteriorates – Health status, depression or anxiety scores. Advise women that the time taken for ectopic pregnancies to resolve and future fertility outcomes are likely to be the same with either expectant or medical management |
Strong |
|
Methotrexate treatment for tubal ectopic pregnancy |
|
|
Offer systemic methotrexate to women who have no significant pain and have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35 mm with no visible heartbeat and have a serum hCG level less than 1,500 IU/litre and do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) and are able to return for follow-up |
Strong |
|
Methotrexate should only be offered on a first visit when there is a definitive diagnosis of an ectopic pregnancy, and a viable intrauterine pregnancy has been excluded. Offer surgery where treatment with methotrexate is not acceptable to the woman. For women with ectopic pregnancy who have had methotrexate, take 2 serum hCG measurements in the first week (days 4 and 7) after treatment and then 1 serum hCG measurement per week until a negative result is obtained. If hCG levels plateau or rise, reassess the woman’s condition for further treatment |
Strong |
|
Women receiving methotrexate for the management of tubal ectopic pregnancy can be advised that there is no effect on ovarian reserve |
GPS |
|
It is recommended that women treated with methotrexate wait at least 3 months before trying to conceive again |
GPS |
|
Surgical treatment for tubal ectopic pregnancy |
|
|
Offer surgery as a first-line treatment to women who are unable to return for follow-up after methotrexate treatment or who have any of the following: – an ectopic pregnancy and significant pain – an ectopic pregnancy with an adnexal mass of 35 mm or larger – an ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan – an ectopic pregnancy and a serum hCG level of 5,000 IU/litre or more |
Strong |
|
Offer the choice of either methotrexate or surgical management to women with an ectopic pregnancy who have a serum hCG level of at least 1,500 IU/litre and less than 5,000 IU/litre, who are able to return for follow-up and who meet all of the following criteria: – no significant pain – an unruptured ectopic pregnancy with an adnexal mass smaller than 35 mm with no visible heartbeat – no intrauterine pregnancy (as confirmed on an ultrasound scan). Advise women who choose methotrexate that their chance of needing further intervention is increased and they may need to be urgently admitted if their condition deteriorates |
Strong |
|
Laparoscopy for tubal ectopic pregnancy |
|
|
When surgical treatment is indicated for women with an ectopic pregnancy, it should be performed laparoscopically whenever possible, taking into account the condition of the woman and the complexity of the surgical procedure. |
Strong |
|
Surgeons providing care to women with ectopic pregnancy should be competent to perform laparoscopic surgery. |
Strong |
|
Commissioners and managers should ensure that equipment for laparoscopic surgery is available. |
Strong |
|
Salpingectomy and salpingotomy |
|
|
Offer a salpingectomy to women undergoing surgery for an ectopic pregnancy unless they have other risk factors for infertility |
Strong |
|
Consider salpingotomy as an alternative to salpingectomy for women with risk factors for infertility such as contralateral tube damage |
Conditional |
|
Inform women having a salpingotomy that up to 1 in 5 women may need further treatment. This treatment may include methotrexate and/or a salpingectomy. For women who have had a salpingotomy, take 1 serum hCG measurement at 7 days after surgery, then 1 serum hCG measurement per week until a negative result is obtained |
Strong |
|
Advise women who have had a salpingectomy that they should take a urine pregnancy test after 3 weeks. Advise women to return for further assessment if the test is positive |
Strong |
|
Management of Cervical ectopic pregnancy Cervical dilation and curettage may provoke bleeding. Infiltration of the cervix with a haemostatic vasoconstricting agent, followed by the placement of cervical sutures to temporarily occlude the descending branches of the uterine arteries followed by suction curettage (without dilation) and post-curettage cervical canal balloon tamponade has proven successful in treating first trimester cervical pregnancies. Another treatment option is uterine artery embolisation which has been used in combination with MTX 1B |
Strong |
|
Management of Interstitial and cornual pregnancy |
|
|
The optimal method of treatment for interstitial ectopic pregnancy has not been determined and needs further research. Cases should be managed on an individual patient basis and a consultant Obstetrician/Gynaecologist should be involved in decision making and management. |
GPS |
|
Expectant management of interstitial ectopic pregnancy should be used with caution due to the high mortality associated with rupture of an interstitial ectopic pregnancy but can be considered when β-hCG levels are falling and the pregnancy is non-viable. |
Strong |
|
Intramuscular or local methotrexate treatment may be considered in asymptomatic women who fit the criteria for medical management, with follow up serum β-hCG levels. |
Strong |
|
Surgical management may be considered for interstitial ectopic pregnancy and is required when there is evidence of rupture, with follow up β-hCG levels. |
GPS |
|
Laparoscopic linear cornuostomy is carried out in a similar manner to salpingostomy for EP including allowing spontaneous closure of the corneal incision. |
GPS |
|
Cornual resection is another option. Surgical cornual excision is usually preferred either by laparoscopy or open surgery and avoids the risk of recurrence. |
GPS |
|
Treatment for a rudimentary horn ectopic pregnancy is excision of the rudimentary horn via laparoscopy or laparotomy. |
Strong |
|
Management of ovarian pregnancy |
|
|
Optimum management is resection of the ovarian pregnancy with preservation of healthy ovarian tissue. Follow-up hCG monitoring is recommended. MTX is appropriate for persistent trophoblast and has also been used for primary treatment but is limited in this regard due to the need for laparoscopic and histologic confirmation of diagnosis. |
GPS |
|
Management of Heterotopic pregnancy |
|
|
Clinicians should not offer systemic methotrexate in the presence of a desired intrauterine pregnancy. |
Conditional |
|
Management of Cesarean scar pregnancy |
|
|
We recommend against expectant management of cesarean scar ectopic pregnancy. |
Strong |
|
We suggest that operative resection (with transvaginal or laparoscopic approaches when possible) or ultrasound-guided uterine aspiration be considered for the surgical management of cesarean scar ectopic pregnancy and that sharp curettage alone be avoided. |
Conditional |
|
We suggest intra-gestational methotrexate for the medical treatment of cesarean scar ectopic pregnancy, with or without other treatment modalities. |
Conditional |
|
We recommend that systemic methotrexate alone not be used to treat cesarean scar ectopic pregnancy. |
Strong |
|
In patients who choose expectant management and continuation of a cesarean scar ectopic pregnancy, we recommend repeated cesarean delivery between 34 0/7 and 35 6/7 weeks of gestation. |
Strong |
|
We recommend that patients with a cesarean scar ectopic pregnancy be advised of the risks of another pregnancy and counseled regarding effective contraceptive methods, including long-acting reversible contraception and permanent contraception. |
Strong |
|
Management of abdominal ectopic pregnancy |
|
|
Clinicians may choose either laparotomy or laparoscopy to excise an abdominal pregnancy |
Conditional |
|
Anti-D immunoglobulin prophylaxis |
|
|
Offer anti-D immunoglobulin prophylaxis at a dose of 250 IU (50 micrograms) to all rhesus-negative women who have a surgical procedure to manage an ectopic pregnancy or a miscarriage. |
Strong |
|
Do not offer anti-D immunoglobulin prophylaxis to women who: – receive solely medical management for an ectopic pregnancy. – have a pregnancy of unknown location. |
Strong |
|
Do not use a Kleihauer test for quantifying feto-maternal haemorrhage. |
Strong |
|
Follow up |
|
|
An early pregnancy ultrasound scan at 6 weeks’ gestation should be performed in any subsequent pregnancy due to the increased risk of ectopic pregnancy recurrence. |
Prevention and Treatment of Hypertension in Pregnancy
“last update: 2 July 2025” Download Guideline
– Executive Summary
EHC has developed the present evidence-informed recommendations with a view to promoting the best possible clinical practices for the Prevention and Treatment of Hypertension in Pregnancy.
List of Recommendations
Placenta Accreta Spectrum (PAS): Diagnosis and Management
“last update: 14 July 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on Placenta Accreta Spectrum. The recommendations are intended to provide healthcare professionals with practical guidance on diagnosis and management of Placenta Accreta Spectrum which can significantly reduce complications and improve the outcome for affected women and their infants.
List of Recommendations
|
Recommendation
|
Strength |
|
What are the risk factors for women with placenta accreta spectrum?
|
|
|
The major risk factors for placenta accreta spectrum are history of accreta in a previous pregnancy, previous caesarean delivery and other uterine surgery, including repeated endometrial curettage. This risk rises as the number of prior caesarean sections increases. |
Strong Recommendation |
|
Women requesting elective caesarean delivery for non-medical indications should be informed of the risk of placenta accreta spectrum and its consequences for subsequent pregnancies. |
GPS |
|
How can placenta accreta spectrum be suspected and diagnosed antenatally?
|
|
|
Antenatal diagnosis of placenta accreta spectrum is crucial in planning its management and has been shown to reduce maternal morbidity and mortality. |
Strong Recommendation |
|
Ultrasound assessment of placental location should be part of routine obstetric care, particularly in women undergoing cesarean section delivery. |
GPS |
|
Previous caesarean delivery and the presence of an anterior low-lying placenta or placenta praevia should alert the antenatal care team of the higher risk of placenta accreta spectrum. |
Strong Recommendation |
|
Ultrasound screening and diagnosis of placenta accreta spectrum
|
|
|
Ultrasound imaging is highly accurate when performed by a skilled operator with experience in diagnosing placenta accreta spectrum. |
Strong Recommendation |
|
Refer women with any ultrasound features suggestive of placenta accreta spectrum to a specialist unit with imaging expertise. |
Strong Recommendation |
|
Standardised definitions should be used in reporting and consideration given to using a template. |
GPS |
|
Women with a history of previous caesarean section seen to have an anterior low-lying placenta or placenta praevia at the routine fetal anomaly scan should be specifically screened for placenta accreta spectrum. |
Strong Recommendation |
|
Patients with previous one or more CS and diagnosed as CS scar pregnancy at 5-6 weeks of gestation are at high risk of developing placenta accreta. They should be counseled and referred to a tertiary hospital for termination of pregnancy. |
Strong Recommendation |
|
Is there a role for magnetic resonance imaging (MRI) in the diagnosis of placenta accreta spectrum?
|
|
|
Clinicians should be aware that the diagnostic value of MRI and ultrasound imaging in detecting placenta accreta spectrum is similar when performed by experts. |
Strong Recommendation |
|
MRI may be used to complement ultrasound imaging to assess the depth of invasion and lateral extension of myometrial invasion, especially with posterior placentation and/or in women with ultrasound signs suggesting parametrial invasion. |
GPS |
|
Women with a history of previous cesarean delivery or uterine surgery who are found to have an anterior low-lying placenta or placenta previa should be considered at increased risk for placenta accreta spectrum, even if imaging does not confirm the diagnosis. |
GPS |
|
Where should women with placenta accreta spectrum be cared for?
|
|
|
Women diagnosed with placenta accreta spectrum should be cared for by a multidisciplinary team in a specialist centre with expertise in diagnosing and managing invasive placentation. |
GPS |
|
Prevention and treatment of anemia during the antenatal period is recommended for women with placenta praevia, a low-lying placenta or accreta as for any pregnant woman. |
GPS |
|
Delivery for women diagnosed with placenta accreta spectrum should take place in a specialist centre with logistic support for immediate access to blood products, adult intensive care unit and neonatal intensive care unit by a multidisciplinary team with expertise in complex pelvic surgery. |
Strong Recommendation |
|
When should delivery be planned for women with placenta accreta spectrum?
|
|
|
In the absence of risk factors for preterm delivery in women with placenta accreta spectrum, planned delivery at 35+0 to 36+6 weeks of gestation provides the best balance between fetal maturity and the risk of unscheduled delivery. |
GPS |
|
Planning delivery of women with suspected placenta accreta spectrum
|
|
|
Once the diagnosis of placenta accreta spectrum is made, a contingency plan for emergency delivery should be developed in partnership with the woman, including the use of an institutional protocol for the management of maternal hemorrhage. |
GPS |
|
What should be included in the consent form for caesarean section in women with suspected placenta accreta spectrum?
|
|
|
Any woman giving consent for caesarean section should understand the risks associated with caesarean section in general, and the specific risks of placenta accreta spectrum in terms of massive obstetric hemorrhage, increased risk of lower urinary tract damage, the need for blood transfusion and the risk of hysterectomy. |
Strong recommendation |
|
Additional possible interventions in the case of massive hemorrhage should also be discussed, including cell salvage and interventional radiology where available. |
Conditional recommendation |
|
What healthcare professionals should be involved?
|
|
|
The elective delivery of women with placenta accreta spectrum should be managed by a multidisciplinary team, which should include senior anesthetists, obstetricians and gynecologists with appropriate experience in managing the condition and other surgical specialties if indicated. In an emergency, the most senior clinicians available should be involved. |
Strong Recommendation |
|
What anesthetic is most appropriate for delivery?
|
|
|
The choice of anesthetic technique for caesarean section for women with placenta accreta spectrum should be made by the anesthetist conducting the procedure in consultation with the woman prior to surgery. |
GPS |
|
The woman should be informed that the surgical procedure can be performed safely with regional anesthesia but should be advised that it may be necessary to convert to general anesthesia if required and asked to consent to this. |
GPS |
|
What surgical approach should be used for women with placenta accreta spectrum?
|
|
|
Intravenous tranexamic acid should be administered at the commencement of surgery because it reduces intraoperative blood loss. |
Strong recommendation |
|
Caesarean section hysterectomy with the placenta left in situ is preferable to attempting to separate it from the uterine wall. |
Strong recommendation |
|
When the extent of the placenta accreta is limited in depth and surface area, and the entire placental implantation area is accessible and visualised (i.e., completely anterior, fundal or posterior without deep pelvic invasion), uterus preserving surgery may be appropriate, including partial myometrial resection. |
Conditional recommendation |
|
Uterus preserving surgical techniques should only be attempted by surgeons working in teams with appropriate expertise to manage such cases and after appropriate counselling regarding risks and with informed consent. |
Conditional recommendation |
|
There are currently insufficient data to recommend the routine use of ureteric stents in placenta accreta spectrum. The use of stents may have a role when the urinary bladder is invaded by placental tissue. |
GPS |
|
What surgical approach should be used for women with placenta percreta?
|
|
|
There is limited evidence to support uterus preserving surgery in placenta percreta and women should be informed of the high risk of peripartum and secondary complications, including the need for secondary hysterectomy. |
GPS |
|
When is interventional radiology indicated?
|
|
|
Larger studies are necessary to determine the safety and efficacy of interventional radiology before this technique can be advised in the routine management of placenta accreta spectrum. |
Strong recommendation |
|
How are women with undiagnosed or unsuspected placenta accreta spectrum best managed at delivery?
|
|
|
If at the time of an elective repeat caesarean section, where both mother and baby are stable, it is immediately apparent that placenta percreta is present on opening the abdomen, the caesarean section should be delayed until the appropriate staff and resources have been assembled and adequate blood products are available. This may involve closure of the maternal abdomen and urgent transfer to a specialist unit for delivery. |
GPS |
|
In case of unsuspected placenta accreta spectrum diagnosed after the birth of the baby, the placenta should be left in situ and an emergency hysterectomy performed. |
GPS |
The diagnosis and management of endometriosis
“last update: 28 July 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on diagnosis and management of female pelvic endometriosis. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of female pelvic endometriosis. resulting in improving health outcomes for people with this potentially disabling condition.
List of Recommendations
|
Recommendation |
Strength |
|
Diagnosis of endometriosis |
|
|
Symptoms: Clinicians should consider the diagnosis of endometriosis in individuals presenting with the following cyclical and non-cyclical signs and symptoms: dysmenorrhea, deep dyspareunia, dysuria, dyschezia, painful rectal bleeding or haematuria, shoulder tip pain, catamenial pneumothorax, cyclical cough/haemoptysis/ chest pain, cyclical scar swelling and pain, fatigue, and infertility |
GPS |
|
Signs: Offer an abdominal and pelvic examination to people with suspected endometriosis to identify abdominal masses and pelvic signs, such as reduced organ mobility and enlargement, tender nodularity in the posterior vaginal fornix, and visible vaginal endometriotic lesions. |
GPS |
|
If rectal endometriosis is suspected, a rectal examination may also be proactively performed to confirm the status of the bowel wall. |
GPS |
|
Diagnostic imaging |
|
|
Women with suspected endometriosis, further diagnostic steps, including imaging, should be considered even if the clinical examination is normal |
Strong |
|
Clinicians are recommended to use imaging (US or MRI) in the diagnostic work-up for endometriosis, but they need to be aware that a negative finding does not exclude endometriosis, particularly superficial peritoneal disease |
Strong |
|
Offer a transvaginal ultrasound scan to all women with suspected endometriosis, even if pelvic or abdominal examination is normal, to: identify ovarian endometriomas and deep endometriosis |
Conditional |
|
If a transvaginal scan is declined or not appropriate, consider transabdominal ultrasound scan of the pelvis |
GPS |
|
Do not use pelvic MRI as the primary investigation to diagnose endometriosis in people with symptoms or signs suggestive of endometriosis. |
Conditional |
|
Consider pelvic MRI to assess the extent of deep endometriosis involving the bowel, bladder or ureter |
Conditional |
|
Laparoscopy: surgical diagnosis |
|
|
In patients with negative imaging results, or where empirical treatment (hormonal contraceptives or progestogens) was unsuccessful, consider offering laparoscopy for the diagnosis and treatment of suspected endometriosis |
GPS |
|
Laparoscopic identification of endometriotic lesions should be confirmed by histopathologic examination of the lesions. However, a negative histology does not entirely rule out the disease |
GPS |
|
The procedure should be performed by a trained laparoscopic surgeon, who should perform and document a systematic inspection of the pelvis and abdomen |
GPS |
|
Biomarker: Do not use serum CA125 to diagnose endometriosis. |
Strong |
|
Treatment of endometriosis associated pain |
|
|
Pain control in endometriosis |
|
|
For women with pain associated with endometriosis-, consider a short trial (for example, 3 months) of a non-steroidal anti-inflammatory drug (NSAID) alone or in combination with paracetamol, if not contraindicated. If such a trial does not provide adequate pain relief, consider other forms of pain management and referral for secondary or tertiary care center. |
GPS |
|
Advise patients that there is no evidence for or against the use of anti-neuropathic medications for pain associated with endometriosis |
GPS |
|
Women with endometriosis should be referred to a pain specialist and/or a condition-specific specialist at any stage if: • pain is severe and unresponsive to simple analgesics. • the pain substantially limits daily activities. • any underlying health condition has deteriorated. |
Conditional |
|
Hormonal treatment for endometriosis |
|
|
It is recommended to offer women hormone treatment (combined hormonal contraceptives, progestogens, GnRH agonists or GnRH antagonists) as one of the options to reduce endometriosis-associated pain |
Strong |
|
The GDG recommends that clinicians take a shared decision-making approach and take individual preferences, side effects, individual efficacy, costs, and availability into consideration when choosing hormone treatments for endometriosis-associated pain |
GPS |
|
When appropriate a levonorgestrel-releasing intrauterine system or an etonogestrel-releasing subdermal implant to reduce endometriosis-associated pain can be used |
Strong |
|
It is recommended to prescribe women GnRH agonists to reduce endometriosis-associated pain, although evidence is limited regarding dosage or duration of treatment |
Strong |
|
The GDG recommends that GnRH agonists are prescribed as second line (for example if hormonal contraceptives or progestogens have been ineffective) due to their side-effect profile |
GPS |
|
Clinicians should consider prescribing combined hormonal add-back therapy alongside GnRH agonist therapy to prevent bone loss and hypoestrogenic symptoms |
Strong |
|
In women with endometriosis-associated pain refractory to other medical or surgical treatment, it is recommended to prescribe aromatase inhibitors, as they reduce endometriosis-associated pain. Aromatase inhibitors may be prescribed in combination with oral contraceptives, progestogens, GnRH agonists or GnRH antagonists |
Strong |
|
Surgical management for endometriosis |
|
|
Laparoscopic management should be done by an expert in laparoscopic surgery |
GPS |
|
When surgery is performed, clinicians may consider excision instead of ablation of endometriosis to reduce endometriosis-associated pain |
Conditional |
|
It can be concluded that LUNA is not beneficial as an additional procedure to conventional laparoscopic surgery for endometriosis, PSN is beneficial for treatment of endometriosis-associated midline pain as an adjunct to conventional laparoscopic surgery |
GPS |
|
When performing surgery in women with ovarian endometrioma, clinicians should perform cystectomy instead of drainage and coagulation, |
Strong |
|
When performing surgery for ovarian endometrioma, specific caution should be used to minimize ovarian damage |
Strong |
|
Clinicians can consider performing surgical removal of deep endometriosis, as it may reduce endometriosis-associated pain and improves quality of life |
Conditional |
|
The GDG recommends that patients undergoing surgery particularly for deep endometriosis are informed on potential risks, benefits, and long-term effect on quality of life |
GPS |
|
Due to the heterogeneity of patient population, presentation, surgical approaches and techniques, it is difficult to make definitive recommendations on the specific techniques to be applied for the treatment of pain associated with deep endometriosis |
GPS |
|
In case of bowel endometriosis, a conservative approach should be chosen whenever possible. |
GPS |
|
Hysterectomy for endometriosis associated pain |
|
|
Clinicians can consider hysterectomy (with or without removal of the ovaries) with removal of all visible endometriosis lesions, in those women who no longer wish to conceive and failed to respond to more conservative treatments. |
Conditional |
|
The GDG recommends that when hysterectomy is performed, a total hysterectomy is preferred |
GPS |
|
When a decision is made whether to remove the ovaries, the long-term consequences of early menopause and possible need for hormone replacement therapy should be considered |
GPS |
|
Studies should evaluate factors that can be assessed prior to surgery and can predict a clinically meaningful improvement of pain symptoms. Such prognostic markers can be used to select patients that may benefit from endometriosis surgery |
GPS |
|
Women may be offered postoperative hormone treatment to improve the immediate outcome of surgery for pain in women with endometriosis if not desiring immediate pregnancy |
Conditional |
|
Non-medical interventions in endometriosis |
|
|
No recommendations can be made for any specific non-medical intervention (Chinese medicine, nutrition, electrotherapy, acupuncture, physiotherapy, exercise, and psychological interventions) to reduce pain or improve quality of life measures in women with endometriosis, as the potential benefits and harms are unclear. |
GPS |
|
Treatment of endometriosis associated infertility |
|
|
Ovarian suppression |
|
|
In infertile women with endometriosis, clinicians should not prescribe ovarian suppression treatment to improve fertility. |
Strong |
|
Women seeking pregnancy should not be prescribed postoperative hormone suppression with the sole purpose to enhance future pregnancy rates. |
strong |
|
Those women who cannot attempt to or decide not to conceive immediately after surgery may be offered hormone therapy as it does not negatively impact their fertility and improves the immediate outcome of surgery for pain |
Conditional |
|
In infertile women with endometriosis, clinicians should not prescribe pentoxifylline, other anti-inflammatory drugs or letrozole outside ovulation-induction to improve natural pregnancy rates. |
Strong |
|
Surgical treatment |
|
|
The GDG recommends that the decision to perform surgery should be guided by the presence or absence of pain symptoms, patient age and preferences, history of previous surgery, presence of other infertility factors, ovarian reserve, and estimated Endometriosis Fertility Index (EFI). |
GPS |
|
Operative laparoscopy could be offered as a treatment option for endometriosis-associated infertility in rASRM stage I/II endometriosis as it improves the rate of ongoing pregnancy. |
Conditional |
|
Clinicians may consider operative laparoscopy for the treatment of endometrioma-associated infertility as it may increase their chance of natural pregnancy, although no data from comparative studies exist. |
Conditional |
|
Although no compelling evidence exists that operative laparoscopy for deep endometriosis improves fertility, operative laparoscopy may represent a treatment option in symptomatic patients wishing to conceive. |
Conditional |
|
Assessing the need for assisted reproduction after surgery |
|
|
Women should be counselled of their chances of becoming pregnant after surgery. To identify patients that may benefit from ART after surgery, the Endometriosis Fertility Index (EFI) should be used as it is validated, reproducible and cost-effective. The results of other fertility investigations such as their partner’s sperm analysis should be taken into account. |
GPS |
|
Medically assisted reproduction |
|
|
IUI with endometriosis |
|
|
In infertile women with rASRM stage I/II endometriosis, clinicians may perform intrauterine insemination (IUI) with ovarian stimulation, instead of expectant management or IUI alone, as it increases pregnancy rates. |
Conditional |
|
Although the value of IUI in infertile women with rASRM stage III/IV endometriosis with tubal patency is uncertain, the use of IUI with ovarian stimulation could be considered. |
Conditional |
|
ART in women with endometriosis |
|
|
ART can be performed for infertility associated with endometriosis, especially if tubal function is compromised, if there is male factor infertility, in case of low EFI and/or if other treatments have failed |
Conditional |
|
A specific protocol for ART in women with endometriosis cannot be recommended. Both GnRH antagonist and agonist protocols can be offered based on patients’ and physicians’ preferences as no difference in pregnancy or live birth rate has been demonstrated |
Conditional |
|
Women with endometriosis can be reassured regarding the safety of ART since the recurrence rates are not increased compared to those women not undergoing ART. |
Conditional |
|
In women with endometrioma, clinicians may use antibiotic prophylaxis at the time of oocyte retrieval, although the risk of ovarian abscess formation following follicle aspiration is low. |
GPS |
|
Medical therapies as an adjunct to MAR |
|
|
The extended administration of GnRH agonist prior to ART treatment to improve live birth rate in infertile women with endometriosis is not recommended, as the benefit is uncertain. |
Strong |
|
There is insufficient evidence to recommend prolonged administration of the COC/progestogens as a pre-treatment to ART to increase live birth rates. |
Conditional |
|
Surgical therapies as an adjunct to MAR |
|
|
Clinicians are not recommended to routinely perform surgery prior to ART to improve live birth rates in women with rASRM stage I/II endometriosis, as the potential benefits are unclear. |
Strong |
|
Clinicians are not recommended to routinely perform surgery for ovarian endometrioma prior to ART to improve live birth rates, as the current evidence shows no benefit and surgery is likely to have a negative impact on ovarian reserve. |
Strong |
|
Surgery for endometrioma prior to ART can be considered to improve endometriosis-associated pain or accessibility of follicles. |
GPS |
|
The decision to offer surgical excision of deep endometriosis lesions prior to ART should be guided mainly by pain symptoms and patient preference as its effectiveness on reproductive outcome is uncertain due to lack of randomised studies |
Strong |
|
Non-medical management strategies for infertility |
|
|
No recommendation can be made to support any non-medical interventions (nutrition, Chinese medicine, electrotherapy, acupuncture, physiotherapy, exercise, and psychological interventions) to increase fertility in women with endometriosis. The potential benefits and harms are unclear. |
GPS |
|
Fertility Preservation |
|
|
In case of extensive ovarian endometriosis, clinicians should discuss the pros and cons of fertility preservation with women with endometriosis. The true benefit of fertility preservation in women with endometriosis remains unknown |
Strong |
|
Impact of endometriosis on pregnancy and pregnancy outcome |
|
|
Patients should not be advised to become pregnant with the sole purpose of treating endometriosis, as pregnancy does not always lead to improvement of symptoms or reduction of disease progression. |
strong |
|
Complications related directly to pre-existing endometriosis lesions are rare, but probably under-reported. Such complications may be related to their decidualization, adhesion formation/stretching and endometriosis-related chronic inflammation. Although rare, they may represent life-threatening situations that may require surgical management. |
GPS |
|
Clinicians should be aware that there may be an increased risk of first trimester miscarriage and ectopic pregnancy in women with endometriosis. |
Strong |
|
Clinicians should be aware of endometriosis-associated complications in pregnancy, although these are rare. As these findings are based on low/moderate quality studies, these results should be interpreted with caution and currently do not warrant increased antenatal monitoring or dissuade women from becoming pregnant. |
Strong |
|
Endometriosis recurrence |
|
|
Prevention of endometriosis recurrence When surgery is indicated in women with an endometrioma, clinicians should perform ovarian cystectomy, instead of drainage and electrocoagulation, for the secondary prevention of endometriosis-associated dysmenorrhea, dyspareunia, and non-menstrual pelvic pain. However, the risk of reduced ovarian reserve should be taken into account |
Strong |
|
Clinicians should consider prescribing the postoperative use of a levonorgestrel-releasing intrauterine system (52 mg LNG-IUS) or a combined hormonal contraceptive for at least 18–24 months for the secondary prevention of endometriosis-associated dysmenorrhea |
Strong |
|
After surgical management of ovarian endometrioma in women not immediately seeking conception, clinicians are recommended to offer long-term hormone treatment (e.g. combined hormonal contraceptives) for the secondary prevention of endometrioma and endometriosis-associated related symptom recurrence. |
Strong |
|
For the prevention of recurrence of deep endometriosis and associated symptoms, long-term administration of postoperative hormone treatment can be considered |
Conditional |
|
Long-term administration of progestogen may reduce the recurrence of ovarian endometriotic cysts. |
Conditional |
|
Treatment of recurrent endometriosis Any hormone treatment or surgery can be offered to treat recurring pain symptoms in women with endometriosis |
Conditional |
|
|
|
|
Clinical symptoms: In adolescents, clinicians should take a careful history and consider the following symptoms as suggestive of the presence of endometriosis: -chronic or a-cyclical pelvic pain, particularly combined with nausea, dysmenorrhea, dyschezia, dysuria, dyspareunia -cyclical pelvic pain |
Strong |
|
Clinical examination In case of virgin written informed consent from the patient and her parents before rectal examination |
GPS |
|
The recommendations for clinical examination in adults can be applied. |
GPS |
|
Imaging In case of virgin written informed consent from the patient and her parents before rectal u/s |
GPS |
|
Pelvic imaging with ultrasonography, regardless of findings on pelvic examination, also should be considered during evaluation for secondary dysmenorrhea. |
GPS |
|
Transvaginal ultrasound is recommended to be used in adolescents in whom it is appropriate non virgin, as it is effective in diagnosing ovarian endometriosis. |
Strong
|
|
If a transvaginal scan is not appropriate, MRI, trans abdominal, trans-perineal, or trans rectal scan may be considered. |
Conditional |
|
Laboratory parameters Serum biomarkers (e.g., CA-125) are not recommended for diagnosing or ruling out endometriosis in adolescents. |
Strong |
|
Diagnostic laparoscopy In adolescents with suspected endometriosis where imaging is negative and imperical medical treatments (with NSAIDs and/or hormonal contraceptives) have not been successful, diagnostic laparoscopy may be considered. |
Conditional |
|
The appearance of endometriosis may be different in an adolescent than in an adult woman. In adolescents, endometriotic lesions are typically clear or red and can be difficult to identify for gynecologists unfamiliar with endometriosis in adolescents. |
GPS |
|
If a laparoscopy is performed, clinicians may consider taking biopsies to confirm the diagnosis histologically, although negative histology does not entirely rule out the disease. |
Strong |
|
Medical treatment Nonsteroidal anti-inflammatory drugs should be the mainstay of pain relief for adolescents with endometriosis. |
GPS |
|
In adolescents with severe dysmenorrhea and/or endometriosis-associated pain, Clinicians should prescribe hormonal contraceptives or progestogens |
Strong |
|
In adolescents with laparoscopically confirmed endometriosis and associated pain in whom hormonal contraceptives or progestogen therapy failed, clinicians may consider prescribing GnRH agonists combined with add-back therapy for up to 1 year, as they are effective and safe. |
Conditional |
|
If GnRH agonist treatment is considered, it should be used only after careful consideration and discussion of potential side effects and potential long-term health risks with a practitioner in a secondary or tertiary care setting |
GPS |
|
Combined medical and surgical treatment. In adolescents with endometriosis, clinicians should consider postoperative hormone therapy, as this may suppress recurrence of symptoms |
Strong |
|
Menopause and Endometriosis |
|
|
Treatment of endometriosis in postmenopausal women |
|
|
Clinicians may consider surgical treatment for postmenopausal women presenting with signs of endometriosis and/or pain to enable histological confirmation of the diagnosis of endometriosis |
conditional |
|
Clinicians should acknowledge the uncertainty towards the risk of malignancy in postmenopausal women. If a pelvic mass is detected, the work-up and treatment should be performed according to national oncology guidelines |
GPS |
|
For postmenopausal women with endometriosis-associated pain, clinicians may consider aromatase inhibitors as a treatment option especially if surgery is not feasible. |
Conditional |
|
Menopausal symptoms in women with a history of endometriosis |
|
|
Clinicians may consider combined menopausal hormone therapy (MHT) for the treatment of postmenopausal symptoms in women (both after natural and surgical menopause) with a history of endometriosis |
Conditional |
|
Clinicians should avoid prescribing estrogen-only regimens for the treatment of vasomotor symptoms in postmenopausal women with a history of endometriosis, as these regimens may be associated with a higher risk of malignant transformation |
Strong |
|
Clinicians should continue to treat women with a history of endometriosis after surgical menopause with combined estrogen-progestogen at least up to the age of natural menopause. |
GPS |
|
Menopause-related major health concerns in women with endometriosis |
|
|
Clinicians should be aware that women with endometriosis who have undergone an early bilateral salpingo-oophorectomy as part of their treatment have an increased risk of diminished bone density, dementia, and cardiovascular disease. It is also important to note that women with endometriosis have an increased risk of cardiovascular disease, irrespective of whether they have had an early surgical menopause |
GPS |
|
Extra pelvic endometriosis |
|
|
Clinicians should be aware of symptoms of extra-pelvic thoracic endometriosis, such as cyclical shoulder pain, cyclical spontaneous pneumothorax, cyclical cough, or nodules which enlarge during menses. |
GPS |
|
It is advisable to discuss diagnosis and management of extra-pelvic & thoracic endometriosis in a multidisciplinary team in a center with sufficient expertise |
GPS |
|
For abdominal extra-pelvic endometriosis, surgical removal is the preferred treatment, when possible, to relieve symptoms. Hormone treatment may also be an option when surgery is not possible or acceptable |
Conditional |
|
Asymptomatic endometriosis |
|
|
Treatment Clinicians should inform and counsel women about any incidental finding of endometriosis |
GPS |
|
Clinicians should not routinely perform surgical excision/ablation for an incidental finding of asymptomatic endometriosis at the time of surgery |
Strong |
|
Clinicians should not prescribe medical treatment in women with incidental finding of endometriosis |
Strong |
|
Monitoring Routine ultrasound monitoring of asymptomatic endometriosis can be considered. |
Conditional |
|
Primary prevention of endometriosis |
|
|
Although there is no direct evidence of benefit in preventing endometriosis in the future, women can be advised of aiming for a healthy lifestyle and diet, with reduced alcohol intake and regular physical activity |
Conditional |
|
The usefulness of hormonal contraceptives for the primary prevention of endometriosis is uncertain |
Conditional |
Recommendations on The Clinical Interventions For The Prevention of The Primary Cesarean Section
“last update: 4 August 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on the clinical interventions for the safe prevention of the primary cesarean section. The recommendations are intended to provide healthcare professionals caring for pregnant women with practical guidance on how to safely avoid the primary cesarean section.
List of Recommendations
|
Strength of Recommendation |
|
|
1. Measures During ANC and Before Labor |
|
|
|
|
|
1.1.1. Discuss the benefits and risks of both caesarean and vaginal birth with women, taking into account their circumstances, concerns, priorities and plans for future pregnancies. (See Appendix I) |
GPS
|
|
1.1.2. Fetal presentation should be assessed and documented beginning at 36 0/7 weeks of gestation to guide the plan of management. |
GPS
|
|
1.2. Breech Presentation & Other Fetal Malpresentation |
|
|
1.2.1. Offer women who have an uncomplicated singleton breech pregnancy after 36+0 weeks, external cephalic version by an experienced obstetrician, unless: ➡️ the woman is in established labor ➡️ there is fetal compromise ➡️ the woman has ruptured membranes or vaginal bleeding ➡️ the woman has any other medical conditions (for example, severe hypertension) that would make external cephalic version inadvisable. |
Conditional
|
|
1.2.2. Before carrying out a caesarean birth for an uncomplicated singleton breech pregnancy, carry out an ultrasound scan to check that the baby is in the breech position. Do this as late as possible before the caesarean birth procedure. |
GPS
|
|
1.3. Suspected Fetal Macrosomia |
|
|
1.3.1 Cesarean delivery to avoid potential birth trauma should be limited to estimated fetal weights of at least 4500 g in women without diabetes and at least 4000 g in women with diabetes. |
GPS
|
|
1.4. Twin Gestations |
|
|
1.4.1. Perinatal outcomes for twin gestations in which first twin is in cephalic presentation are not improved by cesarean delivery. Thus, women with either cephalic/cephalic presenting twins or cephalic/non-cephalic presenting twins should be counseled to attempt vaginal delivery. |
Strong
|
|
1.5. Predicting Caesarean Birth for Cephalopelvic Disproportion |
|
|
1.5.1. Do not use pelvimetry for decision making about mode of birth. |
Strong
|
|
1.5.2. Do not use the following for decision making about mode of birth, as they do not accurately predict cephalopelvic disproportion: ➡️ maternal shoe size ➡️ maternal height ➡️ estimations of fetal size (ultrasound or clinical examination). |
GPS
|
|
1.6. Mother-To-Child Transmission of Hepatitis |
|
|
1.6.1 Hepatitis B virus: Do not offer pregnant women with hepatitis B a planned caesarean birth for this reason alone, as mother-to-baby transmission of hepatitis B can be reduced if the baby receives immunoglobulin and vaccination. |
Strong
|
|
1.6.2 Hepatitis C virus: Do not offer women who are infected with hepatitis C a planned caesarean birth for this reason alone. |
Strong
|
|
1.7. Body Mass Index |
|
|
1.7.1. Do not use a BMI of over 50 kg/m2 alone as an indication for planned caesarean birth. |
GPS
|
|
1.8. Cesarean On Maternal Request |
|
|
1.8.1 If a pregnant woman with no medical indication for a caesarean birth requests a caesarean birth: ➡️ discuss and explore the reasons for the request ➡️ address concerns they have about the birth as pain and pain relief options ➡️ discuss the overall benefits and risks of CS birth compared with vaginal birth (See Appendix I) ➡️ Document the discussion and the decision taken |
GPS
|
|
1.8.2. Don’t do cesarean section on request without a written informed consent from the woman indicating that this is a CS on request in absence of a medical or obstetric indication. |
GPS |
|
1.9. Head Engagement in A Primigravida |
|
|
1.9.1 Non-engagement of the head in a primigravida should not be considered as an only factor requiring cesarean birth. |
GPS |
|
2. Measures During Labor |
|
|
2.1. Induction of Labor |
|
|
2.1.1. Before 41 0/7 weeks of gestation, induction of labor generally should be performed based on maternal and fetal medical indications. Inductions at ≥ 41 0/7 weeks of gestation should be performed to reduce risk of cesarean delivery and risk of perinatal morbidity and mortality. |
Strong
|
|
2.1.2 Cervical ripening methods should be used when labor is induced in women with unfavorable cervix.
|
Strong
|
|
2.2. First Stage of Labor: Latent Phase |
|
|
2.2.1 The use of the following definition of the latent phase of the first stages of labor is recommended for practice: The latent first stage is a period of time characterized by: ➡️ Painful uterine contractions and ➡️ variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labors. |
Strong
|
|
2.2.2 A prolonged latent phase (eg, >20 hours in nulliparous women and >14 hours in multiparous women) should not be an indication for cesarean delivery. |
Strong
|
|
2.2.3. These durations are not recommended as an indication for intervention when maternal and fetal condition are reassuring. |
Strong
|
|
2.2.4. If slow progress is suspected, assess to identify: ➡️ Developing complications ➡️ Reassuring maternal and fetal condition ➡️ Emotional and physical needs |
Strong
|
|
2.3. First Stage of Labor: Active Phase |
|
|
2.3.1. The use of the following definition of the active phase of the first stages of labor is recommended for practice: ➡️ The active first stage is a period of time characterized by regular painful uterine contractions, and a substantial degree of cervical effacement and more rapid cervical dilatation from 5 cm until full dilatation for first and subsequent labors. |
Strong
|
|
2.3.2 Use a partogram with a 4-hour action line to monitor progress of women in spontaneous labor with an uncomplicated singleton pregnancy at term starting in the active phase, to reduce the likelihood of caesarean birth. |
GPS
|
|
2.3.3. Regarding the Partogram: A minimum cervical dilatation rate of 1 cm/hour throughout active first stage is not recommended for identification of normal labor progression and a slower than 1-cm/hour cervical dilatation rate alone should not be a routine indication for obstetric intervention. |
GPS
|
|
2.3.4. A cervical dilatation of 0.5 cm per hour (2 cm in 4 hours) is considered normal in the active phase. |
GPS
|
|
2.3.5. Protracted labor (slower progress than is usual) is diagnosed when in: · Nulliparous women: a cervical dilatation of < 2 cm in 4 hours is found · Multiparous women: a cervical dilatation of < 2 cm in 4 hours or a slowing in the progress of labor If delay is suspected, check descent and rotation of the baby’s head and changes in the strength, duration and frequency of uterine contractions (uterine atony). |
GPS
|
|
2.3.6. For women with intact membranes in whom delay in the established first stage of labor is confirmed: ➡️ consider amniotomy if membranes are intact, ➡️ oxytocin if inertia was diagnosed and ➡️ a repeat vaginal examination 2 hours later. ➡️ If oxytocin is used, ensure that the time between increments of the dose is no more frequent than every 30 minutes and increase oxytocin until there are 4–5 contractions in 10 minutes. ➡️ If cervical dilatation has increased by less than 2 cm after 4 hours of oxytocin, review is required to assess the need for caesarean section. |
GPS
|
|
2.3.7. Labor may not naturally accelerate until a cervical dilatation threshold of 5 cm is reached. Therefore, the use of medical interventions to accelerate labor and birth (such as oxytocin augmentation or caesarean section) before this threshold is not recommended, provided fetal and maternal conditions are reassuring. |
Strong
|
|
2.3.8. Arrest in labor (complete cessation of progress) is diagnosed at cervical dilatation of 6 cm or more with ruptured membranes and no or limited cervical change for 4 hours of adequate contractions. |
Strong
|
|
2.3.9. Cesarean delivery for active-phase arrest in first stage of labor should be reserved for women ≥ 6 cm of dilation with ruptured membranes who fail to progress despite 4 hours of adequate uterine activity |
Strong
|
|
2.4. Fetal Heart Rate Monitoring |
|
|
2.4.1. Intermittent auscultation of the fetal heart rate with either a Doppler ultrasound device or Pinard fetal stethoscope is recommended for healthy pregnant women in labor. |
Strong
|
|
2.4.2. Standardization of protocol of the intermittent auscultation is important for health care planning and medico-legal purposes and, therefore, the WHO adopted the following protocol: · Interval: Auscultate every 15–30 minutes in active first stage of labor, and every 5 minutes in the second stage of labor. · Duration: Each auscultation should last for at least 1 minute; if the FHR is not always in the normal range (i.e. 110–160 bpm), auscultation should be prolonged to cover at least three uterine contractions. · Timing: Auscultate during a uterine contraction and continue for at least 30 seconds after the contraction
|
Strong
|
|
2.5. Second stage of labor |
|
|
2.5.1. The use of the following definition and duration of the second stage of labor is recommended for practice: The second stage is the period of time between full cervical dilatation and birth of the baby, during which the woman has an involuntary urge to bear down, as a result of expulsive uterine contractions. |
STRONG
|
|
2.5.2. The duration of the second stage varies from one woman to another: ➡️ In first labor, birth is usually completed within 2 hours ➡️ In subsequent labors, birth is usually completed within 1 hour. |
GPS
|
|
2.5.3. Before diagnosing arrest of labor in second stage, if maternal and fetal conditions permit, allow for: ➡️ At least 1 h of pushing in multiparous women ➡️ At least 2 h of pushing in nulliparous women Longer durations may be appropriate on individualized basis (e.g., with use of epidural analgesia or with fetal malposition) as long as maternal and fetal conditions are reassuring and progress is being documented. |
Strong
|
|
2.5.4. Delay in active second stage is diagnosed when: ➡️ In nulliparous woman (any of): either insufficient flexion/rotation/descent within 1 hour or the second stage duration is > 2 hours. ➡️ In multiparous woman (any of): either insufficient flexion/rotation/descent within 30 minutes or the second stage duration is > 1 hour. Longer durations may be appropriate where maternal and fetal condition is optimal. |
GPS
|
|
2.5.5. A specific absolute maximum length of second stage (passive plus active) has not been identified. Rather than rigid time limits, base decision-making on continuing assessment of: ➡️ Maternal physical and emotional condition ➡️ Fetal condition ➡️ Progress of labor ➡️ Maternal preferences |
GPS
|
|
2.5.6. Operative vaginal delivery in second stage of labor by experienced and well-trained physicians should be considered safe, acceptable alternative to cesarean delivery. Training in, and ongoing maintenance of, practical skills related to operative vaginal delivery should be encouraged. |
Strong
|
Primary Postpartum Hemorrhage
“last update: 17 December 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on prevention and management of postpartum hemorrhage. The recommendations are intended to provide healthcare professionals with practical guidance on risk prevention, treatment interventions and improving health outcomes for cases of postpartum hemorrhage.
List of Recommendations
|
Recommendation |
Strength |
|
1. PREVENTION OF POSTPARTUM HEMORRHAGE |
|
|
1.1 Risk Assessment: |
|
|
1.1.1. Risk factors for PPH may present antenatally or intrapartum; care plans must be modified as and when risk factors arise. |
GPS |
|
1.1.2. Clinicians must be aware of risk factors for PPH and should take these into account when counselling women about place of delivery. |
GPS |
|
1.1.3. Women with known risk factors for PPH should only be delivered in a hospital with a blood bank on site. |
Strong |
|
1.1.4. An individualized risk assessment for postpartum hemorrhage should be documented upon arrival to a labor unit and updated throughout labor and delivery. |
Strong |
|
1.2 Risk Factors |
|
|
1.2.1 Consider the following antenatal risk factors for PPH · Age > 35 · Obesity (BMI >35) · More than 3 prior births · Previous PPH · Previous Cesarean section with placenta previa or PAS · Previous uterine surgery · Presence of uterine fibroid · Multiple pregnancy · Polyhydramnios · Fetal macrosomia · Anemia · Known coagulopathy or other bleeding disorders |
GPS |
|
1.2.2. Consider the following intrapartum risk factors for PPH · Oxytocin use in labor · Prolonged second stage · Prolonged third stage · Retained placenta · Manual removal of placenta · Assisted vaginal birth · Cesarean section whether elective or emergency · Perineal trauma · Uterine rupture · General anaesthesia · Infection · Non-cephalic presentation · Precipitate labor |
GPS |
|
1.3. Antenatal Risk Management |
|
|
1.3.1. Antenatal anemia |
|
|
1.3.1.1. Antenatal anemia should be investigated and treated appropriately as this may reduce the morbidity associated with PPH. |
Strong |
|
1.3.2. Maternal blood disorders |
|
|
1.3.2.1. Involve specialist physician to: · Optimize coagulation profile prior to birth · Advise on birth options (e.g. mode of birth) 1.3.2.2. Seek anesthetic opinion regarding options for analgesia during labor and birth |
Strong |
|
1.3.3. Abnormal placentation |
|
|
1.3.3.1. Determine placental site and if abnormal placental adherence is suspected (PAS): · Refer to a center equipped for placenta accreta management. · Involve multidisciplinary team including urologist, general surgeon, vascular surgeon, hematologist, senior anaesthetist and ICU specialist in preoperative planning. |
Strong |
|
1.4. Intrapartum Risk Management |
|
|
1.4.1. Management of third stage of labor The use of uterotonics for prevention of PPH during the third stage of labor is recommended for all births. |
Strong |
|
1.4.2. Cord clamping: 1.4.2.1. Late cord clamping (performed approximately 1 to 3 minutes after birth) is recommended for all births while initiating simultaneous essential newborn care. 1.4.2.2. Early cord clamping (<1 minute after birth) is not recommended unless the neonate is asphyxiated and needs to be moved immediately for resuscitation. |
Strong |
|
1.4.3. Controlled cord traction: 1.4.3.1 Consider Controlled cord traction (CCT) as part of active/modified active management of third stage as it may. |
Strong |
|
1.4.3.2. Providers employing CCT should only do so after signs of placental separation, and traction should be performed with uterine contraction as these measures reduce the risk of uterine inversion, cord avulsion, and partial detachment of the placenta. |
Strong |
|
1.5. Prophylactic Uterotonics: |
|
|
1.5.1. Oxytocin: 1.5.1.1. In most circumstances, oxytocin is the prophylactic uterotonic of choice. 1.5.1.2 For vaginal birth · If vaginal birth with IV access: Oxytocin 10 IU IV injected slowly over 3–5 minutes is recommended in preference to IM · If vaginal birth without IV access: Oxytocin 10 IU IM · To be transferred ransfer to rational: When compared with IM, IV oxytocin reduces the risk of PPH, need for blood transfusion 60-62 and incidence of retained placenta with no significant difference in side effects (e.g. hypotension and tachycardia) between routes 60,61 1.5.1.3. For CS birth: · Oxytocin 5 IU IV over 1–2 minutes · Monitor for hemodynamic impact · Avoid rapid IV bolus administration 1.5.1.4. If cardiovascular compromise exists (e.g. hypovolemia, shock, cardiac disease), use caution with IV administration. Rational it may result in transient hemodynamic instability 61, 65 |
Strong |
|
1.5.2. Ergometrine: 1.5.2.1 Ergometrine can be given IM or, in life-saving circumstances, as a slow IV injection. 1.5.2.2. Ergometrine should not be used in patients with essential or gestational hypertension, or in patients on HIV protease inhibitors. 1.5.2.3. Though undisputedly extremely effective, potential adverse effects limit ergometrine to a second-line agent. |
Conditional |
|
1.5.3. Carbetocin: 1.5.3.1. Routinely use oxytocin in preference to carbetocin if vaginal birth and cold-chain storage of oxytocin can be guaranteed (e.g. hospital setting). 1.5.3.2. If vaginal birth and cold-chain storage of uterotonics cannot be guaranteed: · Carbetocin is an effective alternative uterotonic · IM is preferred route of administration 1.5.3.2. If CS birth under regional anesthetic: IV carbetocin may be considered as a cost effective uterotonic 1.5.3.3. If CS birth under general anesthetic: Carbetocin is not recommended due to insufficient evidence. 1.5.3.4. If used: used as a single dose only, not for repeated use |
Conditional |
|
1.5.4. Misoprostol: 1.5.4.1. Not recommended if alternative injectable uterotonics are available 1.5.4.2. Use only if no other injectable uterotonic is available (e.g. due to unexpected birth in low resource setting or if storage conditions for uterotonics are inadequate). 1.5.4.3. The dose is 600 micrograms orally or sublingual single dose immediately after birth 1.5.4.4. If in a low resource setting with limited PPH treatment capability, consider use if: · an injectable uterotonic has been administered AND · continued bleeding is anticipated and/or blood loss is estimated to be greater than or equal to 350 mL |
Conditional |
|
1.6. Tranexamic Acid (TXA) For Prophylaxis in High Risk Women |
|
|
1.6.1. Tranexamic acid can be used as a prophylactic agent as an adjunct to uterotonics in patients at high risk for postpartum hemorrhage. 1.6.2. Use TXA within 3 hours of birth of the baby in a fixed dose of 1 g in 10 mL IV over 10 minutes (100 mg/min i.e. 1 ml /minute) |
Strong |
|
1.7. Immediate Postpartum Risk Management |
|
|
1.7.1. Uterine massage: Sustained uterine massage is not recommended as an intervention to prevent PPH in women who have received prophylactic oxytocin. |
GPS |
|
1.7.2. Uterine tonus assessment: Postpartum abdominal uterine tonus assessment for early identification of uterine atony is recommended for all women. |
Strong |
|
1.7.3. Nipple stimulation & breast feeding: Nipple stimulation and/or early breastfeeding may increase uterine activity but has not been shown to reduce bleeding or incidence of PPH. |
GPS |
|
1.7.4. Observation for women with risk factors in the first 2 hours postpartum: · Vital signs: Respiratory rate, pulse rate, and blood pressure, every 15-30 minutes in the first hour and every 30 minutes in the second hour. · Blood Loss every 15-30 minutes by visualizing the labia and perineum and be alert for slow steady trickle. · Temperature every 30 minutes · Uterine tonus assessment · Urine output: after the first 2 hours · After the first 2 hours continue as clinically indicated |
Strong |
|
2. RECOGNITION OF PPH |
|
|
2.1. General Principles In Diagnosis of PPH |
|
|
2.1.1 Early recognition of postpartum hemorrhage (before deterioration in vital signs) is recommended and should be the goal in order to improve outcomes. |
Strong |
|
2.1.2. Clinical signs and symptoms of hypovolemia should be included in the assessment of PPH. However, clinicians should be aware that the signs of hypovolemic shock become less sensitive in pregnancy. |
Strong |
|
2.1.4. Consider initiation of response to PPH when there is excessive bleeding in the first 24 hours post birth, judged clinically, or through estimation of blood loss volume (> 500 ml after VD or 1000ml after CS), or changes in the hemodynamic state. |
Strong |
|
2.2 Visual Assessment of The Amount of Postpartum Blood Loss |
|
|
2.2.1. Visual estimation of blood loss is always subjective and can be imprecise and often leads to underestimation of large volumes or overestimation of small volumes 2.2.2. When conducting visual assessment of blood loss, consider the volume, nature and speed of blood loss. 2.2.3. Simulated scenarios and pictorial guides may improve staff accuracy |
Conditional |
|
2.3. Quantitative Measurement of The Amount of Postpartum Blood Loss |
|
|
2.3.1 Consider that quantitative measurement, provides a more accurate assessment of blood loss when compared with visual estimation. 2.3.2. Consider measurement of blood loss by blood collection drapes for vaginal deliveries,5,10 or the weighing of swabs and weigh blood-soaked items (e.g. linen, pads, swabs, drapes) to quantify volume.5,60 If weighing, 1 gram is equivalent to 1 mL blood loss. |
Conditional |
|
2.4. Diagnosis of PPH & Assessment of Hemodynamic Compromise |
|
|
2.4.1. PPH can be minor (500–1000 ml blood loss) or major (more than 1000 ml blood loss). The condition becomes worse if the patient lost >2000 mL of blood. 2.4.2. Diagnose minor PPH (blood loss 500-1000 mL) if there are: · Normal blood pressure · Mild increase in heart rate (but <100 beats/minute) · Palpitation · Lightheadedness 2.4.3. Diagnose major PPH (blood loss from 1000-2000 mL) if there are: · Drop of blood pressure below the original average of the patient · Tachycardia (≥ 100 beats/minute) · Sweating · Weakness |
GPS |
|
2.4.4. Signs of hemodynamic compromise are a late indicator of PPH and may not be evident until large volumes of blood are lost (e.g. up to 25% of total blood volume or greater than 1500 mL). 2.4.5. Don’t wait for the following to diagnose major PPH as blood loss is already >2000 mL and the condition would be severe enough to be of poorer prognosis: · Systolic blood pressure drops below 70-80 mmHg · Tachycardia (120-140 beats/minute) · Restlessness, confusion and pallor · Oliguria 2.4.6. Conversely, compromise may occur earlier in women with: · Gestational hypertension with proteinuria · Anemia · Dehydration · Small stature · Cardiac disease |
Strong |
|
3. RESPONDING TO AND MANAGEMENT OF PPH |
|
|
3.1. General Principles In Responding To PPH |
|
|
3.1.1. Bleeding after labor is an emergency and responding to it should not be delayed and should start as early as possible and goes hand in hand with the rest of management (Communication with the patient, senior staff, resuscitation investigation, and monitoring). |
GPS |
|
3.1.2. Use an approach that involves maintaining hemodynamic stability while simultaneously identifying and treating the cause of blood loss. |
Strong |
|
3.1.3. The urgency and measures undertaken to resuscitate and arrest hemorrhage need to be tailored to the amount of blood loss (which is usually underestimated), the patient general condition, and the degree of shock. |
Strong |
|
3.1.4 The GDG recommends adoption of the EMOTIVE bundle (Early detection, Massage, Oxytocics, Tranexamic acid, IV fluids, Examination & Escalation) as the standard first-response protocol for all cases of postpartum hemorrhage. Initiate all components within 15 minutes of PPH diagnosis to ensure rapid, standardized, and evidence-based management, with ongoing monitoring and escalation as needed, see Appendix II. |
Strong |
|
3.2. Communication And Multidisciplinary Care: |
|
|
3.2.1. Communication with the patient and her birthing partner is important, and clear information of what is happening should be given from the outset. 3.2.2. Relevant staff with an appropriate level of expertise should be alerted of PPH. 3.2.3. The first-line obstetric and anesthetic staff should be alerted when women present with minor PPH (blood loss 500–1000 ml) without clinical shock 3.2.4. A multidisciplinary team involving senior members of staff should be called to attend to women with major PPH (blood loss of more than 1000 ml) and ongoing bleeding or clinical shock |
GPS |
|
3.3. Responding To & Managing Minor PPH |
|
|
3.3.1. Measures for minor PPH (blood loss 500–1000 ml) without clinical shock: · Establish IV access: 2 wide bore IV cannulas (Orange 14G & Grey 16G) are to be inserted. 14G for fluid and blood replacement & 16G for pharmacologic therapy · Urgent venipuncture and obtain 20 ml of blood for: o Grouping & cross-matching o Full blood count o Coagulation screen, including fibrinogen, if available · Pulse, respiratory rate and blood pressure recording every 15 minutes · Commence warmed crystalloid infusion. · If bleeding is rapid and patient continues to bleed, consider starting the full protocol for major PPH. · In minor PPH, there are no firm criteria for initiating red cell transfusion. The decision to provide blood transfusion should be based on both clinical and hematological assessment. |
GPS |
|
3.4. Identification of The Cause (the 4Ts) |
|
|
3.4.1. If blood loss after delivery seems increased, start the measures of minor PPH and immediately assess for the Tone of the uterus, the presence of Trauma, any retained Tissue or Thrombin activity. · Tone: massage the fundus to see whether the uterus is atonic or well contracted. · Tissue: retained placental fragment. Inspect the placenta for a missing part. Also suspect retained placental fragment or pieces of membranes as a cause if there is atonic fundus unresponsive to uterotonics. · Trauma: if fundus is well contracted, blood clotting is ok and no placental remnants, explore birth canal for improperly repaired birth tract injuries. · Thrombin: The fundus is contracted (may be atonic) and the blood is not clotting. · Other unknown causes: if all of the above is normal, assess for uterine rupture/ inversion, concealed bleeding (e.g. vault hematoma, internal hemorrhage after CS) and non-genital causes (e.g. subcapsular liver rupture). |
GPS |
|
3.5. Responding To & Managing Major PPH |
|
|
3.5.1. Full protocol for major PPH (blood loss greater than 1000 ml) and continuing to bleed or clinical shock: · A and B: assess Airway and Breathing · C – evaluate Circulation · Position the patient flat · Insert two peripheral cannulas (14 gauge) if not inserted before · Immediately draw 20 mL of blood for: o Cross-matching (4 units of blood minimum) o Full blood count o Coagulation screen (PT, INR, aPTT including fibrinogen, if available) o Chemistry profile (Serum Creatinine, SGOT, SGPT, Albumin, LDH, Blood Sugar) · Keep the woman warm using appropriate available measures · Transfuse blood as soon as possible. · Until blood is available, infuse up to 3.5 L of warmed crystalloids as Lactated Ringer’s (1–2 mL for every 1 mL of blood loss)2 · Stop fluid once blood is ready. · The best equipment available should be used to achieve rapid warmed infusion of fluids. · Special blood filters should not be used, as they slow infusions. · If actively bleeding, transfuse early and do not wait unnecessarily for laboratory results and use clinical assessment as the main determinant 3.5.2. Blood transfusion: · 3.5.2.1. If actively bleeding, transfuse early, do not wait unnecessarily for laboratory results. The clinical picture should be the main determinant of the need for blood transfusion and time should not be unnecessarily spent awaiting laboratory results. · 3.5.2.2. Packed RBCs: o Provide emergency blood (Packed RBCs) with immediate issue of group O, rhesus D (RhD)-negative, with a switch to group-specific blood as soon as feasible. o Single Hb/hematocrit estimations may be misleading and can lead to delays in initiating red cell transfusion, serial measurements may be helpful to monitor ongoing progress. · 3.5.2.2. Transfusion of FFP: o Administration of FFP should be guided by coagulation profile test results and whether bleeding is continuing. o But if coagulation profile results are not available and bleeding is continuing, after 4 units of red blood cells, 4 units of FFP should be infused until test results are known. o If coagulation profile results are not available, early FFP should be considered for conditions with a suspected coagulopathy, such as placental abruption or amniotic fluid embolism, or where detection of PPH has been delayed. o If prothrombin time/activated partial thromboplastin time is more than 1.5 times normal and hemorrhage is ongoing, more units of FFP are likely to be needed to correct coagulopathy. · 3.5.2.3. Clinicians should be aware that these blood components must be ordered as soon as a need for them is anticipated, as there will always be a short delay in supply because of the need for thawing. 3.5.3. Cryoprecipitate For Fibrinogen Replacement · A plasma fibrinogen level of greater than 2 g/l should be maintained, if test is available, during ongoing PPH. · Cryoprecipitate should be used for fibrinogen replacement. · Physician should be aware that fibrinogen below 3 g/l and especially below 2 g/l is associated with progression of bleeding, increased RBC and blood component requirements, and the need for invasive procedures. 3.5.4. Transfusion of platelets · During PPH, platelets should be transfused when the platelet count is less than 75 × 109/l (75000 / mm3) based on laboratory monitoring. · The platelets should ideally be group compatible. RhD-negative women should receive RhD-negative platelets. 3.5.5. Use Continued Resuscitation with lab-guided replacement to maintain the following lab parameters: · Hb greater than 8 gm% · Platelet count greater than 50 × 109 /l (50000/mm3) · Prothrombin time (PT) less than 1.5 times normal · Activated partial thromboplastin time (APTT) less than 1.5 times normal · Fibrinogen level greater than 2 g/l. |
GPS |
|
3.5.5. Tranexamic acid (TXA) 3.5.5.1. Tranexamic acid can be used in all patients as an adjunct to uterotonics in the setting of postpartum hemorrhage regardless of whether the bleeding is due to genital tract trauma or other causes. 3.5.5.2. Give TXA as early as possible, ideally within 3 hours of birth, in a fixed dose of 1 g in 10 mL (100 mg/mL) IV at 1 mL per minute (i.e., over 10 minutes). 3.5.5.3. A second dose of 1 g IV may be administered if bleeding continues after 30 minutes of the first dose or for bleeding that stops but restarts within 24 hours of completing the first dose. |
Strong |
|
4. MONITORING AND INVESTIGATIONS IN MAJOR PPH |
|
|
4.1 Immediate venipuncture (20 ml) for: · Cross-matching (4 units of Packed RBCs minimum) · FBC · Coagulation screen (PT, INR, aPTT including fibrinogen, if available) · Chemistry profile (Serum Creatinine, SGOT, SGPT, Albumin, LDH, Blood Sugar) · Repeat as necessary 4.2 Continuous pulse, blood pressure and respiratory rate recording (preferably using oximeter, electrocardiogram and automated blood pressure recording when available) and Monitor temperature every 15 minutes. 4.3. Foley’s catheter to monitor urine output 4.4. Documentation of fluid balance, blood, blood products and procedures. 4.5. Consider transfer to intensive therapy unit once the bleeding is controlled or monitoring at high dependency unit on delivery suite, if appropriate. 4.6. Consider objective scoring system for monitoring as the MEOWS Score (see Appendix II) |
GPS |
|
5. ROLE OF THE ANESTHETIST IN THE MANAGEMENT OF PPH |
|
|
The management of PPH requires a multidisciplinary approach: Allow the anesthetist to play a crucial role in maintaining hemodynamic stability and, in determining and administering the most appropriate method of anesthesia. |
Strong |
|
6. PAIN MANAGEMENT |
|
|
Consider pain relief requirements during initial resuscitation and all subsequent treatments |
GPS |
|
7. PHARMACOLOGICAL AND MECHANICAL STRATEGIES IN MANAGEMENT OF PPH |
|
|
7.1. Clinicians should be prepared to use a combination of pharmacological, mechanical and surgical methods to arrest PPH. These methods should be directed towards the causative factor. |
Strong |
|
7.2. When uterine atony is perceived to be a cause of the bleeding, then a sequence of pharmacological and mechanical measures (in the form of uterine massage and urinary bladder catheterization) should be instituted until the bleeding stops. |
Strong |
|
7.3 Stopping the bleeding should not be delayed and should start as early as possible and goes hand in hand with the rest of management above (Communication and multidisciplinary approach, Resuscitation, Investigation, and Monitoring) |
GPS |
|
7.4. The most common cause of primary PPH is uterine atony. The initial management of PPH should, therefore, involve measures to stimulate myometrial contractions. Thus, mechanical and pharmacological measures should be instituted/administered as needed. 7.5. Palpate the uterine fundus and rub it to stimulate contractions and expel its contents (‘rubbing up the fundus’) 7.6. Ensure that the bladder is empty (Foley catheter & leave in place) 7.7 First line pharmacological therapy for uterine atony (Oxytocin): · Give oxytocin 5 IU IV over 1-2 minutes (even if had the prophylactic dose before). The dose may be repeated, only once, after five minutes but consider the maximum dose for IV oxytocin which is 10 IU IV. · Rapid IV bolus administration may cause hypotension, tachycardia, arrhythmia and myocardial ischemia. · Continue with oxytocin IV infusion 40 IU in 500 mL of either 0.9% sodium chloride (saline) or compound sodium lactate (Ringer’s lactate) at a rate of 5-10 IU/hour via: o Using ordinary IV line about adjust it to deliver 20-40 drop/minute o Infusion pump, if available, equals to 62.5–125 mL per hour o Minimum infusion duration is 2 – 4 hours; use clinical judgement. · Oxytocin infusion may be a safer alternative to a bolus dose of oxytocin in some women (e.g. major cardiovascular disorders) · If the patient had induction of labor (IOL) with oxytocin, you may use the same infusion but at increased rate. · If IV access unavailable or delayed, oxytocin 10 IU IM can be administered · If carbetocin has already been given, consider non-oxytocin uterotonic instead 7.8 Supplemental therapy if no adequate response: give the following: 7.8.1. Ergometrine maleate: o 0.25 – 0.5 mg IV over 1-2 minutes (dilute 250 micrograms in 5 mL 0.9% sodium chloride) that may be repeated every 5 minutes to a maximum of 1 mg o It is contraindicated with retained placenta, severe hypertension, pre-eclampsia, eclampsia severe/persistent sepsis, renal, hepatic, vascular, or cardiac disease 7.8.2. Misoprostol: · Consider misoprostol if alternative uterotonics unavailable or contraindicated (e.g. asthma, hypertension) or if bleeding not effectively controlled with oxytocin. · Give 800 mcg sublingual (rapid onset of action with side effects more likely) · Or 1000 mcg per rectum (slow absorption but prolonged effect) · Consider clinical circumstances when determining optimal route · Side effects: Hyperthermia is a common side effect (>38 C is common) and malignant hyperthermia > 40 C has been reported in 1 – 14% of cases |
GPS |
|
8. SURGICAL TREATMENTS OF PPH |
|
|
8.1. If pharmacological measures fail to control the hemorrhage, surgical interventions should be initiated sooner rather than later and the most experienced, anesthetist and obstetrician should be called to be involved in the management. |
Strong |
|
8.2. Transfer the patient to the operative theatre flat with high-flow oxygen and perform an examination under anesthesia for the exclusion of the presence of remnants (to be evacuated if present) and dealing with any birth tract injuries if found |
Strong |
|
8.3. Bimanual Compression: The use of bimanual uterine compression is recommended as a temporary measure until appropriate care is available for the treatment of PPH due to uterine atony after vaginal delivery |
Strong |
|
8.4. Intrauterine balloon tamponade: · If bimanual compression has been effective consider the use of intrauterine balloon tamponade (e.g. Bakri Balloon) as balloon is an appropriate first-line ‘surgical’ intervention for most women where uterine atony is the only or main cause of hemorrhage after the success of bimanual uterine compression. · After insertion, assess blood loss: · If bleeding continues, balloon tamponade may be ineffective—review aetiology of PPH, check balloon placement and consider other surgical interventions. · If bleeding ceases on insertion, monitor fundal height, uterine cramping and signs of increased blood loss regularly · Balloon is left for 6 hours if bleeding stopped and removed in presence of senior staff lest the return of bleeding. |
Strong |
|
8.5. If bimanual compression is ineffective or balloon tamponade fail: · Consider exploratory laparotomy when less invasive approaches fail to control bleeding. In the setting of a vaginal delivery, it is common to use a midline vertical abdominal incision for laparotomy, to optimize exposure and reduce risk of surgical bleeding. In the setting of cesarean birth, the existing surgical incision may be used. · Conservative surgical interventions (compression sutures and/or arterial ligation) may be attempted as a second line, depending on clinical circumstances and available expertise. · Timing is critical. Surgical interventions should be initiated sooner rather than later. · Weigh benefits of conservative versus aggressive management (hysterectomy) |
Strong |
|
8.6 Hemostatic uterine suture (e.g. B-Lynch suture) · Judiciously apply aortic compression (below the level of the renal arteries) as a temporary measure · Consider B-Lynch compression or other compression suture · It is preferable that a laminated diagram of the brace suture technique, as B-lynch suture, be kept in theatre. |
GPS |
|
8.7. Arterial ligation: Stepwise arterial ligation for uterine devascularization may be considered depending on clinical circumstances and available expertise: · Bilateral uterine artery ligation · Bilateral utero-ovarian artery ligation · If expertise available, bilateral internal iliac artery ligation |
GPS |
|
8.8. Hysterectomy: |
|
|
8.8.1. Resort to hysterectomy early (sooner rather than later) especially if: · Life is threatened (hemodynamic unstable patient), · Bleeding continues after use of conservative treatment options · blood transfusion is limited or not an option. · In cases of placenta accreta or uterine rupture. |
Strong |
|
8.8.2. Subtotal (Supra-Vaginal) hysterectomy is quicker and safer in Major PPH and in packing of the abdomen, use hot packs. |
GPS |
|
8.8.3. Ideally and when feasible, a second experienced clinician should be involved in the decision for hysterectomy. |
GPS |
|
8.8.4. In rare situations in spite of compression, arterial ligation and hysterectomy, bleeding from undefined origin might persist in the pelvis (undefined diffuse venous bleeding or bleeding due to DIC). Tight pelvic packing with radio-opaque packs, done by a senior obstetrician, may be a last resort to be followed by temporarily closing the abdomen, stabilization of the patient condition by multidisciplinary team, then reopening the abdomen again to remove the packs and reassess hemostasis after 24-48 hours. |
Conditional |
|
9. RISK MANAGEMENT |
|
|
9.1. Training and Preparation |
|
|
Every maternity unit should have a multidisciplinary protocol for the management of PPH. |
GPS |
|
All staff involved in maternity care should receive training in the management of obstetric emergencies, including the management of PPH. |
Strong |
|
Training for PPH should be multidisciplinary and multiprofessional including team rehearsals. |
Strong |
|
All cases of PPH involving a blood loss of greater than 1500 ml should be the subject of a formal clinical incident review. |
GPS |
|
9.2. Documentation |
|
|
Accurate documentation of a delivery with PPH is essential. |
GPS |
|
9.3. Consent |
|
|
If treatment is likely to affect woman’s fertility, prioritize gaining informed consent. |
Strong |
|
10. Postnatal Care |
|
|
Upon discharge: Educate about signs, symptoms and self-referral regarding persistent or increasing bleeding, infection and risk of secondary PPH, postnatal depression, and venous thromboembolism |
GPS |
|
Oral iron supplementation, either alone or in combination with folic acid, may be provided to postpartum women for 6–12 weeks after delivery for reducing the risk of anemia. |
Conditional |
|
Offer the woman and family debriefing/clinical disclosure by senior team members, preferably by clinicians who were at the event Offer additional opportunities for discussion/debrief six weeks postpartum |
GPS |
The management of nausea and vomiting during pregnancy
“last update: 30 December 2025” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on the management of nausea and vomiting during pregnancy. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of nausea and vomiting during pregnancy resulting in improving health outcomes for people with this condition that may considerable affect fetal and maternal health.
List of Recommendations
Normal Labor
“last update: 30 April 2026” Download Guideline
– Executive Summary
This guideline offers evidence-based recommendations on diagnosis and management of normal labor and delivery. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate care and management of women in normal labor. With the aim that proper management of labor would decrease number of unindicated cesarean sections.
List of Recommendations